Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UB-551
- Development stage
- Unknown
- Lead developer
- UBI
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
UB-551 is a recombinant fusion protein incorporating interferon alpha 8 (IFN-α8), developed by UBI Pharma using its proprietary Single-Chain Immunoglobulin Fusion Proteins Platform. IFN-α8 is a subtype of type I interferon known for its potent antiviral, immunomodulatory, and antiproliferative properties. By utilizing a fusion protein format, UB-551 aims to enhance the stability and therapeutic efficacy of interferon therapy compared to conventional formulations. The drug is being developed for a broad range of indications, including chronic viral hepatitis (HBV and HCV), Behcet's disease, and several oncology targets such as colorectal, breast, and ovarian cancers.
- Other names
- innovative interferon alpha 8interferon alpha 8 fusion protein
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)
Beyond the preview
Go deeper on UB-551.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UB-551.